Kết quả bước đầu hóa xạ trị đồng thời kết hợp hóa trị bổ trợ trước phẫu thuật bệnh nhân ung thư trực tràng giai đoạn II, III=Initial results of neoadjuvant chemoradiation followed by consolidation chemotherapy pre-operative in stage II, III rectal cancer patients

0 Người đánh giá. Xếp hạng trung bình 0

Tác giả: Quang Biểu Bùi, Hải Hoàng Nguyễn, Hồng Thăng Vũ

Ngôn ngữ: vie

Ký hiệu phân loại:

Thông tin xuất bản: Tạp chí Nghiên cứu y học (Đại học Y Hà Nội), 2024

Mô tả vật lý: tr.166-174

Bộ sưu tập: Metadata

ID: 244719

Thêm vào giỏ

Nghiên cứu đánh giá kết quả của phương pháp hóa xạ trị đồng thời kết hợp hóa trị bổ trợ trước phẫu thuật (liệu pháp tân bổ trợ toàn diện) trên bệnh nhân ung thư trực tràng giai đoạn II, III. Nghiên cứu tiến cứu, bao gồm 73 bệnh nhân ung thư trực tràng giai đoạn II, III tại Bệnh viện Trung ương Quân đội 108 và Bệnh viện Ung bướu Nghệ An từ 04/2022 - 11/2023 được điều trị hóa - xạ tiền phẫu 50,4 Gy đồng thời với Capecitabine 825 mg/m2 x 2 lần/ngày x 5 ngày/tuần, theo sau hóa chất củng cố bằng FOLFOX hoặc CAPEOX, phẫu thuật được tiến hành sau khi kết thúc hóa chất. Tuổi trung bình 60,1 ± 10,5, tỷ lệ nam/nữ là 1,43/1. Giai đoạn II, III chiếm tỉ lệ lần lượt là 12,3% và 87,7%. Sau điều trị, có 69,9% giảm giai đoạn u và 82,2% giảm giai đoạn hạch. Tỉ lệ bệnh nhân đáp ứng hoàn toàn trên mô bệnh học (pCR: pathological complete responde) là 30,1%. Tỉ lệ bảo tồn cơ thắt chung là 75,3%, với ung thư trực tràng thấp đạt 46,7%. Các tác dụng không mong muốn chủ yếu độ 1,2.The prospective study evaluated the initial results of neoadjuvant chemoradiation followed by consolidation chemotherapy (total neoadjuvant therapy) in stage II, III rectal cancer patients. 73 patients with stage II and III rectal cancer at 108 Military central hospital and Nghe An Oncology hospital from April 2022 to November 2023 received preoperative chemoradiation of 50.4 Gy concurrent with Capecitabine 825mg/m2, twice a day x 5 days/week
neoadjuvant chemotherapy with FOLFOX or CAPEOX was added then followed by surgery. The mean age was 60.1 ± 10.5 years old, with a male/female ratio of 1.43/1. Stage II and III were 12.3% and 87.7% respectively. After treatment, 69.9% of patients had reduction in the tumor stage and 82.2% of patients had reduction in the lymph node stage. 30.1 % of patients had pathological complete response (pCR). Overall sphincter prevention rate was 75.3%, with low rectal cancer reached 46.7%. Side effects were mainly at grade 1.2.

1. Đọc trực tuyến

1. Đọc trực tuyến

Tạo bộ sưu tập với mã QR